Smartfeed
MHRA statement on products containing Cannabidiol (CBD)
The Medicines and Healthcare products Regulatory Agency has reviewed the classification of products containing CBD and found them to meet the definition of a medicinal product.
Logo for Gov UK
An MHRA spokesperson said:
We have come to the opinion that products containing cannabidiol (CBD) used for medical purposes are a medicine. Medicinal products must have a product licence (marketing authorisation) before they can be legally sold, supplied or advertised in the UK, unless exempt. Licensed medicinal products have to meet safety, quality and efficacy standards to protect public health.
If you use CBD and if you have any questions, speak to your GP or other healthcare professional.
We have written to UK CBD stockists and manufacturers to inform them of our view. We can provide regulatory guidance to any company who may wish to apply for a licence.
Background
This opinion is restricted to products containing cannabidiol (CBD).
MHRA advised manufacturers and suppliers of CBD products that we were reviewing the regulatory status of CBD products prior to this opinion being issued.
The assessment of whether a product is classified as a ‘medicinal product’ is carried out in accordance with the definition of a medicinal product and is not based on whether the product is a risk to consumers. Once a valid application is made the product will be assessed in terms of its safety quality and efficacy in the medical claims made.
Unless exempt, medicines must have a product licence (marketing authorisation) before being placed on the market. Exempt products may be supplied as ‘specials’ by an appropriate prescriber. A ‘special’ can only be supplied in order to meet the special needs of an individual patient and may not be advertised. More information about the ‘specials’ process is available on our website.
MHRA have written to 18 companies to advise them of our opinion.
MHRA is responsible for regulating all medicines and medical devices in the UK. All our work is underpinned by robust and fact-based judgments to ensure that the benefits justify any risks. MHRA is a centre of the Medicines and Healthcare products Regulatory Agency which also includes the National Institute for Biological Standards and Control (NIBSC) and the Clinical Practice Research Datalink (CPRD). The Agency is an executive agency of the Department of Health. www.mhra.gov.uk
Media enquiries
News centre
MHRA
151 Buckingham Palace Road
Victoria
London
SW1W 9SZ
Email
newscentre@mhra.gsi.gov.uk
During office hours:
020 3080 7651 (08:30 - 17:00)
Out of office hours:
07770 446 189 (17:00 - 08:30)